What is the debt of EyeGene this year?
EyeGene has a debt level of -2,289.13 KRW this year.
EyeGene Debt 2024
EyeGene Debt
-2,289.13 KRW
Ticker
185490.KQ
ISIN
KR7185490000
In 2024, EyeGene's total debt was -2,289.13 KRW, a -752.64% change from the 350.75 KRW total debt recorded in the previous year.
EyeGene Aktienanalyse
What does EyeGene do?
EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding EyeGene's Debt Structure
EyeGene's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing EyeGene's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to EyeGene’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in EyeGene’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about EyeGene stock
What was the debt of EyeGene compared to the previous year?
The debt of EyeGene has increased by -752.64% compared to the previous year dropped.
What are the consequences of high debt for investors in EyeGene?
High debt can pose a risk for investors of EyeGene, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of EyeGene?
Low debt means that EyeGene has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from EyeGene affect the company?
An increase in debt of EyeGene can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of EyeGene affect the company?
A reduction in debt of EyeGene can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of EyeGene?
Some factors that can influence the debt of EyeGene include investments, acquisitions, operating costs, and revenue development.
Why are the debts of EyeGene so important for investors?
The debts of EyeGene are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can EyeGene take to change the debt?
To change the debt, EyeGene can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does EyeGene pay?
Over the past 12 months, EyeGene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGene is expected to pay a dividend of 0 KRW.
What is the dividend yield of EyeGene?
The current dividend yield of EyeGene is .
When does EyeGene pay dividends?
EyeGene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of EyeGene?
EyeGene paid dividends every year for the past 0 years.
What is the dividend of EyeGene?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is EyeGene located?
EyeGene is assigned to the 'Health' sector.
Wann musste ich die Aktien von EyeGene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of EyeGene from 7/6/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.
When did EyeGene pay the last dividend?
The last dividend was paid out on 7/6/2024.
What was the dividend of EyeGene in the year 2023?
In the year 2023, EyeGene distributed 0 KRW as dividends.
In which currency does EyeGene pay out the dividend?
The dividends of EyeGene are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von EyeGene
Our stock analysis for EyeGene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
